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Abstract
Biologics have become key agents for the management of Crohn’s disease and ulcerative colitis.
Biosimilars are biological medicines similar to previously authorized biologics and are already
available in some countries. This ECCO Position Statement defines the collective view of
European specialist in inflammatory bowel disease (IBD) concerning biosimilars. Biosimilars are
not comparable to generic small molecules, since both efficacy and toxicity are difficult to
predict due to subtle molecular changes that can have profound effects on clinical efficacy and
immunogenicity. Direct evidence of safety and benefit from clinical trials in IBD, post-marketing
pharmacoviligance, and unequivocal identification of the product as a biosimilar should be
requirements before approval. Switching from an established biologic to a biosimilar to save
costs is likely to be as inappropriate and inefecctive as switching between current biologics that
act on the same target, except when there is loss of response.
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Biological medicines are comprised of proteins or other
substances derived from a biological source.1 Biosimilar
medicines (‘biosimilars’) are biological medicines similar
to other, already authorized, biological medicines, that
are able to enter the market once the patent for the
original product, the reference product, has expired.1
Biosimilar medicines can be broadly categorized into three
categories:
1) products very similar to natural body substances, often used as
replacement therapy, or to enhance the body's innate response;
2) monoclonal antibodies;
3) engineered proteins.
Biological medicines are generally more complex andmuch
larger in size than chemical medicines (sometimes called
‘small molecules’), therefore their precise properties and
characteristics are largely dependent upon the manufacturing
process used.2 Biological medicines are produced by living
systems, such as cell lines, and are therefore subject to
considerable variability in structure and characteristics.
Even after patent expiration, manufacturing processes
do not have to be disclosed, so there are likely to be
appreciable differences in the manufacturing processes of
biosimilars and their reference product.3 Biosimilar prod-
ucts are not generic medical products, so it is therefore
likely that these differences in the manufacturing process
will lead to subtle differences between similar biological
medicines.2
Biosimilars should be distinguished from new generation
biological medicines, sometimes called ‘me too’ biologics.
New generation biological medicines are agents that may
have a similar target to the first-generation product, but are
manufactured independently as new products that are
subject to conventional proof of efficacy and licensing
procedures.
In the EU, biological medicines need to be authorized by
the European Medicines Agency (EMA). The EMA established
a specific legal pathway for approval of biosimilars in 2005,
in which it is recognized that biosimilars cannot be identical
to the primary compound, but must be similar to the original
EU-approved molecules in terms of quality, safety, and
efficacy.1
To date, a total of 19 biosimilar medicines have been
evaluated and 14 authorized in the EU. All currently
authorized biosimilars fall within three product classes:
human growth hormones, erythropoietins and granulocyte
colony stimulating factors.4
2. Why biosimilars?
Use of biological agents is increasing, with new indications
and increased patient demand. Notably, in 2012, it wasestimated that seven of the world's top ten selling drugs
were biological medicines. Sales of biological medicines are
expected to continue to grow at least twice the rate of sales
of small molecules.5,6
Biosimilars have been viewed as potentially cost saving
compared to the reference product, in a manner similar to
the cost savings associated with generic versions of chemical
medicines. However, while generic chemical medicines
and biosimilars have an important role to play in terms of
increasing competition in the marketplace, price reductions
for biosimilars are unlikely to be as substantial as those seen
for generics. This is because biological medicines, including
biosimilars, are more costly to produce and develop than
chemical medicines and their generics. Furthermore, the
regulatory process based on clinical trials of bioequivalence
necessary for the approval of either biological medicines or
biosimilars is more involved and therefore more costly. If
regulatory authorities stipulate the necessity for a safety
registry for biosimilars, this will further add to baseline
costs. Nevertheless, it can still be expected that biosimilars
will be priced below their reference product, which can
therefore be expected to have an impact on the affordability
and availability of biological medicines, making them more
accessible to patients.6
3. Biosimilars in inflammatory bowel disease
▪ The patent on the monoclonal antibody infliximab is due to
expire in the EU
o two biosimilar infliximabs have already filed for EMA regula-
tory approval, one of which is now licensed in South Korea
▪ Special considerations for TNF-alpha antagonists in IBD
o Mechanism of action not completely understood
o No suitable surrogate endpoints to act as pharmacodynamic
markers
o Downstream effects contributing to efficacy remain unclear
o Concomitant medications (e.g. oral immunomodulators) affect
pharmacokinetics and pharmacodynamics
o Methods and interpretation of drug levels and anti-drug
antibodies in IBD remain to be standardized
4. Regulatory requirements in Europe
In 2005, EMA established a specific legal pathway for
the authorization of biosimilars. While EMA recognizes that
it is not possible for biosimilars to be identical to the
reference compound, it is necessary for such agents to be
similar in terms of efficacy and safety, as well as quality.1
Assessment by EMA of applications for biosimilars is
conducted in accordance with the guidelines of the
Committee for Human Medicinal Products (CHMP), which
highlight the studies necessary for demonstrating similarity
of the proposed biosimilar to the reference product. These
studies include pharmacokinetic and pharmacodynamic
studies, both in vitro and animal models, as well as
studies conducted in patients.2,7,8 EMA allows for a
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which the reference product is approved, based on the
extrapolation of data obtained in these indications for
the reference product. Following approval of biosimilars,
rigorous pharmacovigilance is necessary to obtain full infor-
mation regarding the safety profile of biosimilar agents, both
to detect unexpected reactions and to identify any increase in
frequency of predictable adverse events (such as sepsis or
reactivation of tuberculosis) resulting from any lower thresh-
old for treatment. It is noted that EMA guidelines (EMEA/
CHMP/BMWP/42832/2005) state that “Within the authorisa-
tion procedure….Pharmacovigilance systems (as defined in
the current EU legislation) and procedures (including trace-
ability as described in the current EU guidelines) to achieve
this monitoring should be in place when a marketing
authorisation is granted…The compliance of the marketing
authorisation holder with commitments (where appropriate)
and their pharmacovigilance obligations will be closely
monitored.”
5. Position
ECCO believes that the safest and most effective treatments
should be readily available to appropriate patients at the
lowest possible cost. The principal driver of decisions
should, in all cases, be sound scientific evidence and a
“patient first” approach.9 In the very specific case of
biosimilars in IBD, decisions regarding therapeutic equiva-
lence and interchangeability should be taken into consider-
ation and guide principles, which include the following:
▪ The molecular size and complex structure of biological medicines
(and biosimilars) make it extremely difficult to predict thera-
peutic equivalence, because even subtle changes during devel-
opment can cause profound differences in clinical efficacy or
immunogenicity. Such differences can occur even within the
same biological medicine if different manufacturing processes
are used (e.g. different cell lines).
▪ Rules applied to the production of generic chemical medicines
cannot be transferred to biosimilars
▪ Different biological and biosimilar medicines targeting the same
molecule are neither identical in efficacy nor toxicity, even in
the same clinical entity.
▪ A biosimilar proven effective and safe for one indication may not
necessarily be effective and safe for a second indication for
which the reference biological has been shown to be safe and
effective.
▪ Specific evidence obtained in patients with IBD should be
required to establish efficacy and safety for this specific
indication, because experience with currently licensed biological
medicines has already shown that clinical efficacy in IBD cannot
be predicted by effectiveness in other indications, such as
rheumatoid arthritis
▪ Clinical trials should be of large enough size to detect common
adverse events and powered to show equivalence with a
reference biological agent, or conventional superiority
▪ Post-marketing collection of data in both children and adults is
necessary to confirm safety by recording less common but
important potential adverse effects, as well as identifying any
increase in frequency of predictable adverse events contingent
on wider access to treatment.
▪ Any decision to substitute a product should only be made with
the prescribing health care provider's specific approval and
patient's knowledge10▪ Names of biosimilars need clearly to differ from their reference
biological medicine in order to facilitate the collection of data on
safety and efficacy, which would be impossible if confusion
between names will occur6. Conclusion
The overall position of ECCO is that the use of most biosimilars
in patients with IBD will require testing in this particular
patient population, with comparison to the appropriate
innovator product. Although wider access to appropriate use
of biological therapy in IBD and potential direct cost savings
are important, rigorous testing is necessary in patients with
IBD to ensure that appropriate efficacy and safety standards
are met. Final clinical decisions should always be made on an
individual basis, taking into account both circumstances of the
individual patient and prescribing physician.
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